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Abstract
Summary The rationale of this study was to determine the
effect of high-dose vitamin D3 supplementation on bone min-
eral density (BMD). Prediabetic males given vitamin D had
significantly less reduction in BMD at the femoral neck com-
pared to the controls. The clinical implications of our findings
require further investigation.
Introduction Type 2 diabetes mellitus is associated with in-
creased fracture risk, and recent studies show crosstalk be-
tween bone and glucose metabolism. Few studies have inves-
tigated the effect of vitamin D supplementation on the bone
without additional calcium. In the present study, we aimed to
determine whether a high dose of vitamin D3 could improve
bone mass density (BMD) in prediabetic subjects.
Methods The current study was conducted as a secondary
research on a previously performed trial, in which 511 sub-
jects with prediabetes were randomized to vitamin D3
(20,000 IU per week) versus placebo for 5 years. BMD was
measured using dual-energy X-ray absorptiometry (DEXA).
Results Two hundred and fifty-six subjects were randomized
to vitamin D and 255 to placebo. Mean baseline serum 25-
hydroxyvitamin D (25(OH)D) level was 60 nmol/L. Two
hundred and two and 214 in the vitamin D and placebo
groups, respectively, completed BMD measurements, where-
as one in each group was excluded due to use of
bisphosphonates.Males given vitamin D had significantly less
reduction in BMD at the femoral neck measurement site com-
pared to the controls (0.000 versus − 0.010 g/cm2, p = 0.008).
No significant differences between intervention groups were
seen at the total hip measurement site, regarding both males
and females.
Conclusions Vitamin D3 supplementation alone may be ben-
eficial in males with prediabetes, but confirmatory studies are
needed.
Keywords Bonemineral density . Prediabetes . Randomized
controlled trial . VitaminD
Introduction
Diabetes mellitus is one of the world’s most common chronic
diseases, and overall prevalence among adults is estimated to
increase in years to come [1, 2]. Blood glucose is, however,
continuous, and type 2 diabetes mellitus (T2DM) develops
through a prediabetic stage, defined by impaired fasting glu-
cose (IFG) and/or impaired glucose tolerance (IGT) [3, 4].
Such modest disturbances of glucose metabolism may in-
crease the risk of complications traditionally attributed to
T2DM, such as retinopathy, nephropathy, myocardial infarc-
tions, and stroke, and both macro and microvascular damage
appear to precede the onset of overt disease [5, 6].
Recently, it has been argued that the effects of chronically
elevated glucose levels on the bone should be added to the
more well-known complications of inadequately regulated
glucose metabolism [7]. This is in line with the growing evi-
dence of increased fracture risk in patients with T2DM,
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although these individuals are reported to have higher bone
mineral density (BMD) than non-diabetic subjects [8–10]. It
has been hypothesized that the accumulation of advanced
glycation end products, impaired bone healing, and altered
body composition, as well as an increased production of
non-enzymatic cross-links within collagen fibers, have a neg-
ative impact on bone matrix properties [7]. Despite these find-
ings, a recent meta-analysis exploring correlations of abnor-
mal glucose metabolism reported no significant correlations
neither with BMD nor with bone metabolism [11]. However,
the increased propensity to fractures in patients with abnormal
glucose metabolism may be caused by less apparent qualita-
tive changes [12]. The notion of the bone being a true endo-
crine organ and an important regulator of whole-body glucose
metabolism [13, 14] further complicates the relationship. In
any case, improved bone health would be considered
beneficial.
Vitamin D deficiency has been linked to both high blood
glucose levels, insulin resistance, and greater risk of devel-
oping T2DM, although so far, the results of large RCTs do
not support a causal relationship [15]. The role of vitamin D
in maintenance of a healthy, mineralized skeleton through
regulation of calcium and phosphate homeostasis is, how-
ever, well known. Moreover, vitamin D may contribute to
improved bone health independent of its role in calcium
homeostasis.
The active metabolite, 1,25-dihydroxyvitamin D
(1,25(OH)2D), has been suggested to exert local autocrine
and paracrine regulation of bone turnover, in which
1,25(OH)2D can stimulate both bone formation and resorption
[16, 17]. Locally produced 1,25(OH)2D is important for an
optimized communication and coupling mechanism between
osteoblasts and osteoclasts [18], as well as in osteoblast dif-
ferentiation of human bone marrow cells [19, 20]. Moreover,
1,25(OH)2D seems to affect secretion of osteoprotegerin from
mature osteoblasts [21], and both the vitamin D receptor and
the enzyme necessary for activation of 25(OH)D to
1,25(OH)2D, CYP27B1 (1-alphahydroxylase), are present in
bone cells [16]. However, vitamin D may directly inhibit min-
eralization of the bone through increased local pyrophosphate
concentrations [22], and the vitamin D-induced secretion of
osteoprotegerin from osteoblasts has, together with RANKL,
been suggested to stimulate osteoclastogenesis, thereby in-
creasing bone resorption [23]. The latter also applies in states
of vitamin D deficiency where secondary hyperparathyroid-
ism arises, followed by a stimulated production of RANKL
and osteoclastogenesis. Thus, vitamin D may exert biphasic
effects, although consensus regarding this matter is yet to be
reached.
In the present study, we hypothesized that supplementation
with vitamin D could increase BMD in subjects with predia-
betes, and thereby exert a preventive effect on fracture risk in
this potentially exposed group.
Methods
Study design
The design of the study, where the main intention was to
evaluate vitamin D for the prevention of T2DM, has been
described in detail before [15, 24]. In short, prediabetic sub-
jects (IFG (fasting serum glucose 6.0–6.9 mmol/L) and/or
IGT (fasting serum glucose < 7.0 mmol/L and 2-h value
7.8–11.0 mmol/L at oral glucose tolerance test (OGTT) with
75 g glucose)) were included. Subjects were of both sexes,
aged 25–80 years old. Most of them were recruited after par-
ticipation in the sixth survey of the Tromsø Study (2007–
2008) where 4393 subjects with hemoglobin A1c (HbA1c) in
the range 5.0–6.9% (39.9–51.9 mmol/mol) and not previously
diagnosed with diabetes, were invited to an OGTT, which was
completed in 3476 subjects. Among these, 713 had IFG and/
or IGT and were invited by letter to participate in the present
study. In addition, a few other subjects were invited based on
follow-up OGTTs performed in participants in previous stud-
ies [25, 26]. Subjects with primary hyperparathyroidism, gran-
ulomatous disease, history of urolithiasis, cancer diagnosed in
the past 5 years, unstable angina pectoris, myocardial infarc-
tion, or stroke in the past year were excluded. Pregnant or
lactating women, or women of fertile age with no use of con-
traception, were not included.
At the first visit, a brief clinical examination was per-
formed, and questionnaires were filled in. The latter included
questions on medical history and use of dietary supplementa-
tions. Height and weight were measured wearing light cloth-
ing. Fasting blood samples had been collected at the OGTT,
and supplementary non-fasting blood samples were drawn at
this first visit in the study. In all subjects, BMDwas measured
at baseline and at their last visit in the study with dual-energy
X-ray absorptiometry (DEXA) (GE Lunar Prodigy, Lunar
Corporation,Madison,WI, USA) at the femoral neck and total
hip measurement site. The scanner was calibrated daily
against the standard calibration block supplied by the manu-
facturer (aluminum spine phantom), and these measurements
showed no drift throughout the study. The subjects were then
randomized (non-stratified) in a 1:1 ratio to one capsule vita-
min D3 (cholecalciferol 20,000 IU per week (Dekristol; Mibe,
Jena, Germany)) or an identical-looking placebo capsule con-
taining arachis oil (Hasco-Lek, Wroclaw, Poland). New med-
ication was supplied every sixth month, and unused capsules
were returned and counted. The subjects were instructed not to
take vitamin D supplements (including cod liver oil) exceed-
ing 400 IU per day during the study.
For the next 5 years, the subjects met annually for new
OGTTs, supplemental serum sampling, and height, weight,
and blood pressure measurements. As part of a safety moni-
toring, serum calcium and creatinine were measured every
sixth month, in between annual visits. At the annual visits,
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all subjects were asked to fill in the same questionnaires as at
the baseline visit. Adverse events were specifically asked for
at all visits.
If at the annual OGTT the fasting blood glucose was
> 6.9 mmol/L and/or the 2-h value > 11.0 mmol/L, the subject
was considered to have T2DM, thus ending their participation
in the study. These subjects were thereafter retested (if neces-
sary) and followed by their general practitioner. HbA1c was
implemented in the present study as a diagnostic criterion
from November 2012 [15], and thereafter, subjects were
retested with a new HbA1c measurement if HbA1c alone was
≥ 6.5%. If still ≥ 6.5% after retest, subjects were diagnosed
with T2DM, thereby ending their participation. Also, if diag-
nosed elsewhere with T2DM in between visits, participation
in the study was ended.
Subjects with persistent measurements of serum calcium
> 2.55 mmol/L were excluded, as well as subjects who devel-
oped renal stones, or symptoms compatible with renal stones.
In the initial protocol, subjects who during the study were
diagnosed with cancer, coronary infarction, unstable angina
pectoris, or stroke were to be excluded from the study. From
October 2011, this was changed to exclusion of subjects who
during the study developed serious disease making it difficult
or impossible to attend scheduled visits.
Biochemical analyses including serum 25(OH)D were an-
alyzed using the gold standard LC-MSMS method, as previ-
ously described [15].
Statistical analyses
Normal distribution was evaluated by visual inspection of
histograms, and by kurtosis and skewness. Log transformation
was performed where appropriate. Comparisons of interven-
tion groups at baseline were performedwith Student’s t test for
continuous variables, Pearson’s chi-square test for categorical
variables, and Mann-Whitney U test for variables with a non-
normal distribution. For BMD, the mean value of left and right
measures was used for statistical analyses (when both values
could be obtained). If only one side could be measured, this
value was chosen to represent the mean value. Initially, mea-
surements were to be classified as normal if corresponding to a
T-score ≥ − 1.0, and if corresponding to a T-score between
− 1.0 and − 2.5 or ≤ − 2.5 as osteopenic or osteoporotic,
respectively [27]. However, since no male subjects and only
very few female subjects presented with osteoporotic T-
scores, all subjects with T-scores < − 1.0 were classified as
osteopenic. Participants reporting use of bisphosphonates dur-
ing the study were excluded from all statistical analyses.
Predictors of baseline BMD were evaluated with multiple lin-
ear regression, applying forced entry on all predictor variables.
Regarding change in BMD (delta values calculated as BMD at
the last visit in the study minus BMD at baseline), comparison
of the vitamin D and the placebo group was done using
Student’s t test. If significant, change in BMD was further
tested with a linear regression model adjusting for baseline
values [28], observation time and variables significantly
predicting BMD at baseline (Table 2). All subgroups were
analyzed likewise. The incidence of fractures during the study
in the vitamin D and the placebo group was tested with a
binary logistic regression analysis, adjusted for age and BMI.
A power calculation was made for the main endpoint (de-
velopment of T2DM) [15], but a separate power calculation
regarding BMDwas not made. All tests were done two-sided,
and p < 0.05 was considered statistically significant.
Statistical analyses were performed per protocol, using
SPSS software version 24 (IBM Corp, Chicago, IL).
Ethics
Written informed consent for participation in the study was
provided by all subjects who accepted the invitation. The
study was approved by the Regional Committee for Medical
Research Ethics (REK NORD 81/2007) and by the
Norwegian Medicines Agency (2007-002167-27). The trial
is registered at ClinicalTrials.gov (NCT00685594).
Results
A total of 511 subjects were included in the main study on
prevention of T2DM. Ninety-five subjects were excluded due
to missing baseline and/or final BMD measurements, and an
additional two subjects were excluded due to use of
bisphosphonates, thus leaving 414 subjects (201 given vita-
min D and 213 given placebo) for the BMD analyses in the
present study. Among these, 111 in the vitamin D group and
109 in the placebo group completed the 5-year intervention
period. The flow of the study is shown in Fig. 1. Median
observation time was 59 months in both of the male interven-
tion groups (p = 0.738), while a non-significant difference in
observation time was found between the female intervention
groups with a median of 59 months in the vitamin D group
versus 48 months in the placebo group (p = 0.177).
Baseline characteristics of the study participants are shown
in Table 1, and no significant differences between the vitamin
D and the placebo group were observed. The baseline serum
25(OH)D levels were 59.7 ± 22.0 nmol/L in the vitamin D
group and 61.5 ± 20.4 nmol/L in the placebo group. During
the 5-year intervention, mean serum 25(OH)D levels in the
vitamin D group increased to 114.7 ± 27.4 nmol/L, whereas
only minor changes were observed in mean serum 25(OH)D
levels in the placebo group, as shown for males in Figs. 2 and
3. After 1 year, median serum PTH fell from 5.3 ± 2.1 to
5.0 ± 1.8 pmol/L in the vitamin D group, in contrast to an
increase from 5.1 ± 2.1 to 5.2 ± 2.2 pmol/L in the placebo
group (p = 0.005). A similar difference persisted throughout
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the study, both in men and women. The compliance rate was
between 95 and 99% at all visits in both groups.
The baseline characteristics of the 97 subjects excluded due
to missing BMDmeasurements can be found in Supplemental
Table 1. Among these, there were no significant differences
between the 55 subjects given vitamin D and the 42 subjects
given placebo, nor were there any significant differences be-
tween the included (414 subjects) and the excluded (97 sub-
jects) at baseline.
Among the entire study population, a total of 3885 adverse
events were recorded during the 5-year intervention period,
with no significant differences between intervention groups.
Adverse events and side effects, including serious and/or
calcium-specific events, have been described in detail before,
and no serious side effects related to the intervention were
recorded [15]. In the present study, we looked specifically at
incident fractures. A total of 22 fractures were recorded
among the subjects with valid BMD measurements, of which
nine were in men. Of these nine, three fractures were recorded
in the vitamin D group, against six in the placebo group. There
was no significant difference in the number of fractures be-
tween the vitamin D group and the placebo group (adjusting
for age, weight, and height); neither in general (p = 0.868) nor
in stratified analyses (males, p = 0.384 versus females,
p = 0.249).
BMD measurements
There was a non-significant trend (p = 0.06) for interaction
between gender and treatment versus BMD at the femoral
neck site, and thus, we chose to compare intervention groups
regarding change in mean BMD separately for men and wom-
en. Body mass index (BMI) and tobacco use were found to
significantly predict baseline BMD at the femoral neck and
total hip measurement site in both sexes. Age significantly
predicted baseline BMD at the femoral neck and total hip in
females, whereas predicting baseline BMD only at the femo-
ral neck measurement site in males. Additionally, baseline
BMD in males was significantly predicted by serum calcium,
PTH, and creatinine at both measurement sites (Table 2).
There were no statistically significant differences in baseline
BMD in the vitamin D and placebo group neither at the fem-
oral neck, nor at the total hip (Table 3).
In males given vitamin D, there was no reduction in
BMD at the femoral neck from baseline to the last visit in
the study, values being 0.974 g/cm2 at both visits respec-
tively (Table 3). With adjustment for baseline BMD, obser-
vation time, and statistically significant predictors of base-
line BMD (Table 2), this change differed significantly
(p = 0.008) from that in the placebo group, of which corre-
sponding values were 0.984 g/cm2 at baseline and 0.973 g/
cm2 at the final visit (Table 3). At the total hip measurement
site, a marginal difference was found between males given
vitamin D versus placebo (an increase from 1.063 g/cm2 at
baseline to 1.065 g/cm2 at final measurement in the vitamin
D group versus a reduction from 1.078 to 1.075 g/cm2 in the
placebo group). However, this difference did not reach sta-
tistical significance (p = 0.130).
Regarding females, no significant differences were found
between the two groups at either measurement site (Table 3).
Fig. 1 Flowchart of the study
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Subgroup analyses
A subgroup analysis was performed to investigate whether
a more pronounced effect of vitamin D on BMD could be
detected if including only subjects with 25(OH)D levels
below 50 nmol/L. Thus, 68 subjects (47 males) in the vita-
min D group and 63 (40 males) in the placebo group had
serum 25(OH)D levels < 50 nmol /L at base l ine
(Supplemental Table 2). There were no significant differ-
ences between the intervention groups at baseline, and al-
though the same trend was observed, with a marginal in-
crease in BMD during the study among the males given
vitamin D (data not shown), the difference versus the pla-
cebo group did not reach statistical significance (p = 0.072).
Due to the unique opportunity of investigating the effect
of vitamin D supplementation on BMD without any supple-
mental dietary calcium, an additional subgroup analysis
was performed, excluding users of calcium supplements at
baseline and during the study. This analysis rendered 177
subjects (116 males) in the vitamin D group and 177 sub-
jects (118 males) in the placebo group. The two groups were
similar at baseline (Supplemental Table 3), and statistical
regression analyses rendered the same results as in the main
analyses regarding predictors of baseline mean BMD. Also,
a statistically significant interaction term persisted between
gender and intervention (p = 0.048), and stratified linear
regression analyses produced the same results as when cal-
cium users were included, with a statistically significant
change in BMD at the femoral neck in men (p = 0.019),
but not at other measurement sites and with no significant
effects in women (data not shown).
Moreover, to investigate whether the difference between
the vitamin D and the placebo group differed depending on
their prediabetes-diagnosis, the cohort was split into three
groups including those with (1) elevated fasting blood glu-
cose only (6.0–6.9 mmol/L), (2) elevated 2-h values only
(7.8–11.0 mmol/L), and (3) elevated measurements of both
fasting and 2-h values of blood glucose. The sub-cohorts
were then analyzed separately (applying the same statistical
methods as in the main analyses) comparing delta BMD at
the femoral neck and total hip in the vitamin D versus the
placebo group. However, as the results were non-signifi-
cant, these data are not shown.
Finally, subgroup analyses including only subjects with
T-scores < − 1.0 were also carried out; however, few sub-
jects were eligible for such analyses (Table 1), and no sig-
nificant effects were detected at either measurement site
(data not shown).
Table 1 Baseline characteristics of the 414 study subjects
Variables Males Females
Vitamin D
group (n = 125)
Placebo
group (n = 131)
p value Vitamin D
group (n = 76)
Placebo
group (n = 82)
p value
Age (years) 61.1 ± 7.6 61.0 ± 8.8 0.980 62.8 ± 8.3 63.1 ± 9.2 0.841
BMI (kg/m2) 30.0 ± 3.8 30.1 ± 4.4 0.813 30.1 ± 4.3 29.4 ± 4.7 0.311
Tobacco use (%) 24.8 19.1 0.269 18.2 15.9 0.668
Femoral neck BMD (g/cm2) 0.974 ± 0.126 0.984 ± 0.136 0.561 0.918 ± 0.117 0.887 ± 0.137 0.137
Total hip BMD (g/cm2) 1.063 ± 0.137 1.078 ± 0.133 0.393 1.003 ± 0.129 0.961 ± 0.140 0.055
Osteopenia femoral neck (%) 4.8 6.1 0.646 5.3 8.5 0.419
Osteopenia total hip (%) 12.0 14.5 0.555 17.1 12.2 0.382
Serum 25(OH)D (nmol/L) 58.5 ± 23.0 59.0 ± 18.3 0.860 61.7 ± 20.3 65.7 ± 23.0 0.258
Vitamin D supplement usea (%) 30.4 38.9 0.152 36.8 28.0 0.238
Serum calcium, mmol/L 2.31 ± 0.07 2.30 ± 0.08 0.239 2.31 ± 0.07 2.32 ± 0.10 0.573
Calcium supplement use (%) 3.2 6.1 0.271 15.8 24.4 0.179
Serum PTHb (pmol/L) 5.3 (2.2) 5.2 (2.3) 0.443 5.7 (2.2) 5.2 (2.9) 0.514
Serum creatinine (μmol/L) 74.3 ± 12.9 75.4 ± 12.3 0.504 61.0 ± 9.7 61.1 ± 10.8 0.947
HbA1c (%) 6.0 ± 0.3 5.9 ± 0.3 0.097 6.0 ± 0.3 6.0 ± 0.4 0.374
HbA1c (mmol/mol) 42.0 ± 3.0 41.0 ± 3.0 – 42.0 ± 3.0 42.0 ± 4.0 –
Numbers represent mean ± SD, unless otherwise specified. Osteopenia T-score < −1.0
BMI body mass index, BMD bone mass density, 25(OH)D 25-hydroxyvitamin D, PTH parathyroid hormone, HbA1c hemoglobin A1c
a Including cod liver oil
b Non-normal distribution, numbers represent median (IQR)
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Discussion
In the present study, we hypothesized that supplementation
with vitamin D could increase BMD in subjects with predia-
betes, and we found a small, but significant positive effect of
vitamin D supplementation on femoral neck BMD in males.
To our knowledge, this has not been shown before. At the total
hip measurement site, a positive, but non-significant effect
was found. In the females, the vitamin D and the placebo
group did not differ significantly.
To our knowledge, there has only been a few other RCTs
where the effect on BMD of vitamin D given alone has been
studied. Thus, in the review andmeta-analysis by Reid et al. in
2014 [29], 23 studies were identified where the interventions
differed only in vitamin D content. However, vitamin D was
given alone without calcium or other co-interventions in only
seven studies, and among these, none but three included
males. Of the studies including males, one included 50 sub-
jects randomized to 300,000 IU vitamin D per year [30] and
was excluded from the meta-analysis because of a 9-year age
difference between the intervention groups; another included
173 subjects randomized to 400 IU, 800 IU, or placebo over
12 months where a non-significant positive effect at the lum-
bar spine and a significant negative effect at total BMD was
found, however, not including measurements at the femoral
neck [31]; and the third study was excluded due to not avail-
able nor obtainable quantitative data in the original publica-
tion [32]. As far as we are concerned, there has not been any
studies with vitamin D alone that has included males pub-
lished since 2014, and therefore it is fair to say that this has
not been properly examined before.
In the present study, a positive effect of vitamin D supple-
mentation was found only at the femoral neck measurement
site. The femoral neck contains more cortical bone than what
is included in the total hip measurement. The cortical bone is
metabolically less active than the trabecular bone [33], and
previous studies have shown that the cortical bone is also less
responsive to treatment than the trabecular bone [34].
However, in the case of vitamin D deficiency, the secondary
hyperparathyroidism causes bone loss mainly at cortical sites
[35], and suppression of PTH, as was seen in our vitamin D
group, could be the explanation for the BMD increase in the
femoral neck. This was also found in the study by Ooms et al.
[36] where vitamin D3 400 IU/day versus placebo led to an
increase of femoral neck BMD of 2% after 2 years, while there
was no change at the trochanter. Moreover, these observations
fit with the conclusion in the review by Reid et al. [29], in
which a small, but significant effect was found at the femoral
neck, but not at other measurement sites.
Yet, some limitations of our study ought to be considered.
First, change in BMD was not the primary endpoint; thus, the
study design may not have been appropriate. The inclusion
criteria (IFG/IGT) favored subjects with high BMI, which is
traditionally observed to have higher BMD due to mechanical
loading and estrogen production via adipocyte aromatization
[37]. Moreover, only a small number of subjects presented T-
values corresponding with osteopenia, and accordingly, major
improvements in BMD may therefore not have been likely.
The influence of adipose tissue on bone metabolism is, how-
ever, not yet settled as recent studies indicate an inverse asso-
ciation between increased adiposity and low total BMD and
total bone mineral content [38]. Additionally, studies have
shown that T2DM patients are at higher risk of fracture when
Fig. 3 Mean delta BMD (calculated as BMD at the last visit in the study
minus BMD at baseline) at the femoral neck measurement site in the male
intervention groups stratified by length of intervention. The number on
top of the bars represents the number of participants in each subgroup.
Error bars represent 1 SD
Fig. 2 Mean serum 25(OH)D levels during the study in the 125 males in
the vitamin D group and the 131 males in the placebo group. Error bars
represent 1 SD. Asterisks indicate p < 0.001 versus the control group with
Student’s t test
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they have incorrectly treated glucose levels [7]. Thus, an effect
of vitamin D on fracture risk may have been shadowed in the
present trial, as it was originally designed to remove all sub-
jects developing T2DM.
Second, low serum 25(OH)D level was not an inclusion
criteria at baseline, resulting in a wide range of serum
25(OH)D levels among the study participants. Baseline serum
25(OH)D levels were relatively high in the study population,
Table 3 Bone mass density measurements
Vitamin D group Placebo group p value
Males (n) 125 131
Femoral neck BMD (g/cm2) Baseline 0.974 ± 0.126 0.984 ± 0.136 0.561a
Last visit 0.974 ± 0.124 0.973 ± 0.137
Delta 0.000 ± 0.029 − 0.010 ± 0.032 0.008b,c
Total hip BMD (g/cm2) Baseline 1.063 ± 0.137 1.078 ± 0.133 0.393a
Last visit 1.065 ± 0.141 1.075 ± 0.14
Delta 0.002 ± 0.024 − 0.003 ± 0.03 0.149a
Females (n) 76 82
Femoral neck BMD (g/cm2) Baseline 0.918 ± 0.117 0.887 ± 0.137 0.137a
Last visit 0.900 ± 0.120 0.873 ± 0.143
Delta − 0.017 ± 0.034 − 0.015 ± 0.029 0.592a
Total hip BMD (g/cm2) Baseline 1.003 ± 0.129 0.961 ± 0.140 0.055a
Last visit 0.986 ± 0.130 0.943 ± 0.150
Delta − 0.017 ± 0.034 − 0.018 ± 0.029 0.813a
Numbers represent mean ± SD
BMD bone mass density (g/cm2 ), Delta BMDLast visit − BMDBaseline
a Student’s t test
b Linear regression adjusting for baseline values, observation time and predictors of baseline BMD (Table 2)
cR2 = 0.082




p value Total hip
(g/cm2)
p value Femoral neck
(g/cm2)
p value Total hip
(g/cm2)
p value
Age (years) − 0.180 0.003* − 0.112 0.068 − 0.411 < 0.001* − 0.328 < 0.001*




0.258 < 0.001* 0.336 < 0.001*
Tobacco usee (%) − 0.128 0.029* − 0.148 0.013* − 0.151 0.035* − 0.143 0.047*
tbcolw110ptVitamin D
supplement usea,b (%)
0.025 0.668 − 0.021 0.715 − 0.005 0.943 − 0.047 0.519
Calcium supplement usee (%) − 0.075 0.200 − 0.089 0.133 − 0.109 0.139 − 0.132 0.074
Serum 25(OH)D (nmol/L) − 0.006 0.922 − 0.007 0.906 − 0.049 0.534 − 0.047 0.551
Serum calcium (mmol/L) − 0.176 0.003* − 0.128 0.032* − 0.014 0.846 − 0.040 0.577
Serum PTH (pmol/L) − 0.177 0.004* − 0.127 0.041* − 0.161 0.051 − 0.126 0.126
Serum creatinine (μmol/L) 0.171 0.005* 0.131 0.033* 0.119 0.121 0.059 0.445
HbA1c (%) 0.006 0.921 0.059 0.313 0.101 0.165 0.097 0.185
R2 0.238 < 0.001 0.216 < 0.001 0.330 < 0.001 0.323 < 0.001
Numbers represent standardized beta-coefficients and associated p values
a Including cod liver oil
b Coding: 0 = No, 1 = Yes
*Variable included in the linear regression model
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and thus, one might not expect major effects of further sup-
plementation with vitamin D. Nevertheless, a small positive
effect on BMD was observed in men. Moreover, subgroup
analyses of data from subjects with baseline serum 25(OH)D
levels below 50 nmol/L did not show significant effects; how-
ever, this might be explained by lack of statistical power, as
the subgroup consisted of only a small number of subjects.
Third, length of intervention also varied among the study
participants, with approximately 53% completing the 5-year
trial. In short, median observation time was the same in the
vitamin D group compared to the placebo group in males,
while being longer in the female vitamin D group compared
to placebo. However, BMD was found to increase in the male
vitamin D group only, and when comparing median observa-
tion time between intervention groups, differences were non-
significant for both men and women.
Fourth, the effect of vitamin D supplementation on BMD
was not observed in both sexes. However, sexual dimorphism
is not a new nor surprising finding when it comes to skeletal
physiology and bone metabolism [39]. On average, men are
taller, have larger amounts of muscle mass and lower body fat
percentage, as well as having greater peak bone mineral con-
tent and peak trabecular bone volume [40–43]. The establish-
ment of gender differences in the cortical and trabecular bone
is found to be regulated by androgen and estrogen bioactivity,
through a dual mode of action of testosterone on the cortical
and trabecular bone via both the androgen receptor and estro-
gen receptor alpha [37]. If regulation of bone turnover in
women operates through more complex mechanisms than in
men, these mechanisms might override potential effects of
vitamin D supplementation on the bone in women.
However, information regarding history of use and/or current
use of hormonal drugs was not available in the present study,
and adjustments for these factors was therefore not made.
Finally, the proportion of variance of BMD explained (R2)
by the models in our analyses was rather small, and the clinical
implications of our findings may be of modest importance. A
small increase in BMD does not necessarily mean successful
prevention of falls and/or fractures, as the reduction in bone
strength is not only determined by BMD, but also by bone
dimensions, microstructure, and material properties [37].
DEXA is a projectional (two-dimensional) technique, and
thus, cannot truly differentiate between the cortical and trabec-
ular bone. Therefore, such measures of bone health cannot
assess the less apparent qualitative changes that may be pres-
ent due to impaired glucose metabolism. Unfortunately, mea-
surements with techniques allowing a three-dimensional as-
sessment of bone structure and microarchitecture, such as pe-
ripheral quantitative computed tomography (pQCT) scanning,
were not available in the present study.
However, the study has some strengths, as it is the largest,
longest-running, published RCT with vitamin D as the only
intervention, and both dosage and length of intervention ought
to have been sufficient in order to detect an actual effect on
BMD.
In conclusion, we have found a positive effect of vitamin D
on BMD in males, but confirmatory studies are needed, pref-
erably with change in BMD as the primary endpoint, and
levels of 25(OH)D below 50 nmol/L as inclusion criterion.
Additionally, evaluating bone properties with other tech-
niques, such as high-resolution pQCT, may provide valuable
insights.
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